Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: Potential as predictive parameters for response to fluorouracil-based chemotherapy

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 851-856

  Kinoshita, Mizunobu ^a   Kodera, Yasuhiro ^a   Hibi, Kenji ^a   Nakayama, Goro ^a   Inoue, Tamotsu ^a   Ohashi, Norifumi ^a   Ito, Yuichi ^a   Koike, Masahiko ^a   Fujiwara, Michitaka ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Dihydropyrimidine dehydrogenase (DPD); Histoculture drug response assay (HDRA); Orotate phosphoribosyltransferase (OPRT)

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIZATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA SEQUENCE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; MALE; MICRODISSECTION; OPTICAL DENSITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA EXTRACTION; SEQUENCE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OROTATE PHOSPHORIBOSYLTRANSFERASE; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 34247134622     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Leichman CG: Adjuvant therapy for colon cancer 2005: new options in the twenty-first century. Surg Oncol Clin N Am 15: 159-173, 2006.
2. Moertel CG: Chemotherapy for colorectal cancer. New Engl J Med 330: 1136-1142, 1994.
3. Elsaleh H, Powell B, McCaul K et al: p53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 7: 1343-1349, 2001.
4. Liefers GJ, Cleton-Jansen AM, Van de Velde CJH et al: Micrometastases and survival in stage II colorectal cancer. N Engl J Med 339: 223-228, 1998.
5. Adlard JW, Richman SD, Seymour MT and Quirke P: Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3: 75-82, 2002.
6. Matsuyama R, Togo S, Shimizu D et al: Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: Three-gene expression model predicts clinical response. Int J Cancer 119: 406-413, 2006.
7. Ichikawa W, Uetake H, Shirota Y et al: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine- based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9: 786-791, 2003.
8. Ichikawa W, Uetake H, Shirota Y et al: Both gene expression for orotate phosphoribosyl transferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer 89: 1486-1492, 2003.
9. Ochiai T, Mishimura K, Noguchi H et al: Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 118: 3084-3088, 2006.
10. Danenberg PV: Thymidylate synthase-a target enzyme in cancer chemotherapy. Bichim Biophys Acta 473: 73-92, 1977.
11. Heggie GD, Sommadossi JP, Cross DS et al: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206, 1987.
12. Peters GJ, Laurensse E, Leyva A et al: Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 46: 20-28, 1986.
13. Edler D, Kressner U, Ragnhammar P et al: Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival. Clin Cancer Res 6: 488-492, 2000.
14. Salonga D, Danenberg KD, Johnson M et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine Phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
15. Samson DJ, Seidenfeld J, Ziegler K et al: Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22: 3618-3630, 2004.
16. Suda S, Akiyama S, Sekiguchi H et al: Evaluation of the histoculture drug response assay as a sensitivity test for anticancer agents. Surgery Today 32: 477-481, 2002.
17. Abe S, Kubota T, Matsuzaki SW et al: Chemosensitivity test is useful in evaluating the appropriate adjuvant cancer chemotherapy for stage III non-scirrhous and scirrhous gastric cancers. Anticancer Res 19: 4581-4586, 1999.
18. Inokuchi M, Uetake H, Shirota Y et al: Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. Cancer Chemother Pharmacol 53: 391-396, 2004.
19. Isshi K, Sakuyama T, Gen T et al: Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 7: 335-342, 2002.
20. Toi M, Rahman MA, Bando H and Chow LWC: Thymidine Phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 6: 158-166, 2005.
21. Kuramochi H, Hayashi K, Uchida K et al: 5-Fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. Int J Cancer 119: 522-526, 2006.